Moreover, the 36-month beta value for ATHA is 3.02. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for ATHA is 35.70M and currently, short sellers hold a 2.62% of that float. On April 16, 2025, ATHA’s average trading volume was 211.48K shares.
ATHA) stock’s latest price update
The stock price of Athira Pharma Inc (NASDAQ: ATHA) has dropped by -8.78 compared to previous close of 0.26. Despite this, the company has seen a fall of -0.42% in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
ATHA’s Market Performance
Athira Pharma Inc (ATHA) has experienced a -0.42% fall in stock performance for the past week, with a -27.52% drop in the past month, and a -55.45% drop in the past quarter. The volatility ratio for the week is 12.04%, and the volatility levels for the past 30 days are at 12.25% for ATHA. The simple moving average for the past 20 days is -16.19% for ATHA’s stock, with a -78.28% simple moving average for the past 200 days.
Analysts’ Opinion of ATHA
Many brokerage firms have already submitted their reports for ATHA stocks, with Mizuho repeating the rating for ATHA by listing it as a “Neutral.” The predicted price for ATHA in the upcoming period, according to Mizuho is $0.50 based on the research report published on September 19, 2024 of the previous year 2024.
ATHA Trading at -33.78% from the 50-Day Moving Average
After a stumble in the market that brought ATHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.54% of loss for the given period.
Volatility was left at 12.25%, however, over the last 30 days, the volatility rate increased by 12.04%, as shares sank -28.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.59% lower at present.
During the last 5 trading sessions, ATHA fell by -0.42%, which changed the moving average for the period of 200-days by -91.02% in comparison to the 20-day moving average, which settled at $0.2826. In addition, Athira Pharma Inc saw -59.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATHA starting from San Martin Javier, who sale 10,826 shares at the price of $0.56 back on Jan 02 ’25. After this action, San Martin Javier now owns 35,841 shares of Athira Pharma Inc, valued at $6,083 using the latest closing price.
Litton Mark James, the President and CEO of Athira Pharma Inc, sale 25,107 shares at $0.56 during a trade that took place back on Jan 02 ’25, which means that Litton Mark James is holding 242,591 shares at $14,108 based on the most recent closing price.
Stock Fundamentals for ATHA
The total capital return value is set at -2.21. Equity return is now at value -110.77, with -88.52 for asset returns.
Based on Athira Pharma Inc (ATHA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -79.84.
Currently, EBITDA for the company is -100.9 million with net debt to EBITDA at 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.18.
Conclusion
To wrap up, the performance of Athira Pharma Inc (ATHA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
